Published in Alzheimers Dement on May 01, 2010
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
The many faces of tau. Neuron (2011) 2.89
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav (2012) 1.88
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol (2016) 1.76
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp (2011) 1.53
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2012) 1.48
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol (2012) 1.42
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement (2013) 1.15
Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One (2011) 1.12
Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci (2011) 1.09
Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol (2013) 1.09
Rates of decline in Alzheimer disease decrease with age. PLoS One (2012) 1.07
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs (2012) 1.05
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med (2011) 1.05
The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol (2012) 1.05
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med (2010) 1.01
MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers (2013) 1.00
Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies. Front Neurol (2013) 1.00
Perspectives on episodic-like and episodic memory. Front Behav Neurosci (2013) 1.00
MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open (2013) 0.99
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2013) 0.99
Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One (2012) 0.98
Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet (2014) 0.98
Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem Pharmacol (2014) 0.96
Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother (2010) 0.96
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci (2013) 0.94
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94
Mild cognitive impairment and its management in older people. Clin Interv Aging (2015) 0.93
Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol (2012) 0.93
Tau is reduced in AD plasma and validation of employed ELISA methods. Am J Neurodegener Dis (2012) 0.92
Biomarkers in frontotemporal lobar degenerations--progress and challenges. Prog Neurobiol (2011) 0.91
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement (2015) 0.91
Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology (2013) 0.91
Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav Brain Res (2016) 0.90
CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav (2012) 0.90
Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med (2012) 0.90
Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry (2012) 0.90
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement (2015) 0.90
Preoperative cognitive assessment of the elderly surgical patient: a call for action. Anesthesiology (2011) 0.89
A versatile omnibus test for detecting mean and variance heterogeneity. Genet Epidemiol (2014) 0.87
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav (2014) 0.87
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
Association of cancer history with Alzheimer's disease onset and structural brain changes. Front Physiol (2014) 0.86
Ascorbic acid, cognitive function, and Alzheimer's disease: a current review and future direction. Biofactors (2012) 0.86
FASTKD2 is associated with memory and hippocampal structure in older adults. Mol Psychiatry (2014) 0.85
A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations. Hum Brain Mapp (2013) 0.85
Computational genetics analysis of grey matter density in Alzheimer's disease. BioData Min (2014) 0.84
Alzheimer's disease clinical and research update for health care practitioners. J Aging Res (2013) 0.84
Genetic interactions within inositol-related pathways are associated with longitudinal changes in ventricle size. J Alzheimers Dis (2014) 0.84
Traumatic brain injury and age at onset of cognitive impairment in older adults. J Neurol (2016) 0.84
Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. J Alzheimers Dis (2012) 0.83
Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. Alzheimers Dement (2014) 0.82
Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) (2016) 0.82
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. Alzheimers Dement (2012) 0.81
A Dynamical Clustering Model of Brain Connectivity Inspired by the N -Body Problem. Multimodal Brain Image Anal (2013) (2013) 0.81
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci (2010) 0.81
Non-monotonic reorganization of brain networks with Alzheimer's disease progression. Front Aging Neurosci (2015) 0.81
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci (2014) 0.80
Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol (2011) 0.80
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun (2016) 0.80
Alzheimer's disease: The role for neurosurgery. Surg Neurol Int (2014) 0.79
The ADNI Publication Policy: commensurate recognition of critical contributors who are not authors. Neuroimage (2011) 0.79
A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. PLoS One (2015) 0.79
FLOW-BASED NETWORK MEASURES OF BRAIN CONNECTIVITY IN ALZHEIMER'S DISEASE. Proc IEEE Int Symp Biomed Imaging (2013) 0.79
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. PLoS One (2015) 0.78
CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. Acta Neuropathol Commun (2016) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis (2014) 0.78
OPTIMIZING BRAIN CONNECTIVITY NETWORKS FOR DISEASE CLASSIFICATION USING EPIC. Proc IEEE Int Symp Biomed Imaging (2014) 0.78
The "Alzheimer's disease signature": potential perspectives for novel biomarkers. Immun Ageing (2011) 0.78
Drug development in pediatric psychiatry: current status, future trends. Child Adolesc Psychiatry Ment Health (2012) 0.77
High Throughput ELISAs to Measure a Unique Glycan on Transferrin in Cerebrospinal Fluid: A Possible Extension toward Alzheimer's Disease Biomarker Development. Int J Alzheimers Dis (2011) 0.77
OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. Neurodegener Dis Manag (2012) 0.77
The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. Psychiatr Clin North Am (2015) 0.76
Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels. Nat Rev Neurol (2011) 0.76
Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort. Neurology (2016) 0.76
Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alzheimers Res Ther (2016) 0.76
Relative contributions of biomarkers in Alzheimer's disease. Ann Epidemiol (2012) 0.76
The C677T variant in MTHFR modulates associations between blood-based and cerebrospinal fluid biomarkers of neurodegeneration. Neuroreport (2016) 0.75
Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci? PLoS One (2015) 0.75
Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels. BMC Genomics (2016) 0.75
Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights (2013) 0.75
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst) (2017) 0.75
Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging. Front Aging Neurosci (2016) 0.75
Imago Mundi, Imago AD, Imago ADNI. Alzheimers Res Ther (2014) 0.75
Age at injury is associated with the long-term cognitive outcome of traumatic brain injuries. Alzheimers Dement (Amst) (2017) 0.75
Preclinical non-human models to combat dementia. Ann Neurosci (2013) 0.75
Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep (2011) 0.75
Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels. BMC Genomics (2016) 0.75
Genome-wide association study of prolactin levels in blood plasma and cerebrospinal fluid. BMC Genomics (2016) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 4.54
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 2.92
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol (2005) 2.52
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol (2010) 1.29
HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem (2007) 1.22
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. JAMA (2009) 0.94
Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Clin Chem (2009) 0.93
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage (2007) 7.04
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage (2008) 6.58
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The LONI Pipeline Processing Environment. Neuroimage (2003) 5.47
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74